Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Raltegravir and interferon beta in hospitalized COVID-19 patients
IRCT20200412047042N1Phase 3Completed
- Sponsor
- Jahrom University of Medical Sciences
- Start
- Jun 2020
- Modality
- Small Molecules, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, single-blind trial of raltegravir, interferon beta-1a and hydroxychloroquine in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by Jahrom University of Medical Sciences. Primary endpoint: Clinical status. Started Jun 2020; status: completed.
02
Drugs
raltegravirinterferon beta-1ahydroxychloroquine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on IRCT20200412047042N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200412047042N1.